IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company’s newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer’s disease.
February 1, 2024
· 5 min read
